Sale

Market Share

Global Cell Therapy Market Size, Trends, Growth, Forecast: By Type: Stem Cell, Non-Stem Cell (Dendritic Cell, CART-Cell); By Type of Therapy: Autologous, Allogeneic; By Therapeutic Area: Musculoskeletal Disorders, Cardiovascular Diseases, Neurological Disorders, Others; By End User; Regional Anlysis; Supplier Landscape; 2024-2032

Global Cell Therapy Market Share

Market Segmentation by Cell Type is Expected to Drive Substantial Market Growth

Based on the cell type, the market is segmented into stem cells and non-stem cells. The stem cell segment comprises bone marrow derived mesenchymal stem cells, hematopoietic stem cells, umbilical cord derived stem cells, adipose derived stem cells, skin stem cells, and induced pluripotent stem cells, among others, whereas non-stem cells segment includes dendritic cells and car t-cells.

 

The increasing application of stem cells in regenerative medicine and treatment of various diseases is poised to support the cell therapy market growth. Bone marrow derived mesenchymal stem cells (BM-MSC) are taken from bone marrow. They have the ability to differentiate into various cell types and are useful in treating bone and cartilage diseases, and cardiovascular conditions. On the other hand, hematopoietic stem cells (HSC) are taken from bone marrow, peripheral blood, or umbilical cord blood. These cells are responsible for blood cell formation and are increasingly used in the treatment of blood disorders such as leukemia, lymphoma, and anemia.

 

The cell therapy market is also experiencing increased interest in non-stem cell therapies including dendritic cells and CAR T-cells. Such cell therapies are utilized in cancer immunotherapy to destroy cancer cells by leveraging the body's immune system. This segment is anticipated to drive significant market demand with the rising cases of cancer and the need for effective treatment approaches.

 

North America and Europe are Leading the Market Share

Historically, North America dominated the cell therapy market due to the presence of adequate financial support from both government and private bodies in the development of novel cell therapy products and the increased awareness and acceptance of cell therapies among healthcare providers and patients. In the United States, the rising burden of chronic diseases (such as heart disease, cancer, diabetes, obesity, and hypertension) drives the demand for advanced therapies. The US Department of Health and Human Services estimated that around 129 million people in the United States have at least 1 major chronic disease. Since cell therapies can offer promising treatment options for these chronic conditions, the market share is expected to grow in the coming years. Thus, the cell therapy market in North America, particularly in the United States, is anticipated to witness steady growth owing to increased demand for effective cell therapies, growing interest in regenerative medicine and personalized treatment approaches, and rising regulatory support for innovative treatments.

 

Europe also holds a significant share of the overall cell therapy industry, with France and the United Kingdom being some of the dominant regional markets. The increasing research and development activities in France, owing to the presence of some of the leading biotech and research institutions of cell therapy, are bolstering the market growth. In addition, the French biotech institutions, with government support, are contributing to the development of innovative cell therapies. Moreover, the introduction of various favorable government initiatives to aid research activities is invigorating the industry growth, hence contributing to the overall growth of the cell therapy market in the European region. For instance, the United Kingdom government initiated the Human-Induced Pluripotent Stem Cells Initiative (HipSCi) to bring preclinical, clinical, and pharmacological work on stem cells under one institution and increase the accessibility of induced pluripotent stem cell (iPSC) resources to identify new mechanisms.

 

Cell Therapy Market Report Snapshots

Cell Therapy Market Size

Cell Therapy Market Trends

Cell Therapy Market Share

Cell Therapy Companies

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Global  Cell Therapy Market Overview 

    3.1    Global Cell Therapy Market Historical Value (2017-2023) 
    3.2    Global Cell Therapy Market Forecast Value (2024-2032)
4    Vendor Positioning Analysis
    4.1    Key Vendors
    4.2    Prospective Leaders
    4.3    Niche Leaders
    4.4    Disruptors
5    Global Cell Therapy Market Landscape*
    5.1    Global Cell Therapy: Developers Landscape
        5.1.1    Analysis by Year of Establishment
        5.1.2    Analysis by Company Size
        5.1.3    Analysis by Region
    5.2    Global Cell Therapy: Product Landscape 
        5.2.1    Analysis by Type
        5.2.2    Analysis by Type of Therapy
        5.2.3    Analysis by End User
6    Global Cell Therapy Market Dynamics
    6.1    Market Drivers and Constraints
    6.2    SWOT Analysis
        6.2.1    Strengths
        6.2.2    Weaknesses
        6.2.3    Opportunities
        6.2.4    Threats
    6.3    PESTEL Analysis 
        6.3.1    Political 
        6.3.2    Economic 
        6.3.3    Social 
        6.3.4    Technological 
        6.3.5    Legal 
        6.3.6    Environment
    6.4    Porter’s Five Forces Model
        6.4.1    Bargaining Power of Suppliers
        6.4.2    Bargaining Power of Buyers
        6.4.3    Threat of New Entrants
        6.4.4    Threat of Substitutes
        6.4.5    Degree of Rivalry
    6.5    Key Demand Indicators 
    6.6    Key Price Indicators
    6.7    Industry Events, Initiatives, and Trends  
    6.8    Value Chain Analysis
7    Global Cell Therapy Market Segmentation (2017-2032)
    7.1    Global Cell Therapy Market (2017-2032) by Type
        7.1.1    Market Overview
        7.1.2    Stem Cell
            7.1.2.1    Bone Marrow Derived Mesenchymal Stem Cell
            7.1.2.2    Hematopoietic Stem Cells 
            7.1.2.3    Umbilical Cord Derived Stem Cell
            7.1.2.4    Adipose Derived Stem Cell
            7.1.2.5    Skin Stem Cells
            7.1.2.6    Induced Pluripotent Stem Cells
            7.1.2.7    Others
        7.1.3    Non-Stem Cell (Dendritic Cell, CART-Cell)
    7.2    Global Cell Therapy Market (2017-2032) by Type of Therapy 
        7.2.1    Market Overview
        7.2.2    Autologous
        7.2.3    Allogeneic
    7.3    Global Cell Therapy Market (2017-2032) by Therapeutic Area
        7.3.1    Market Overview
        7.3.2    Musculoskeletal Disorders
        7.3.3    Cardiovascular Diseases
        7.3.4    Neurological Disorders
        7.3.5    Oncological Disorders
        7.3.6    Dermatology
        7.3.7    Inflammatory And Autoimmune Disorders
        7.3.8    Others
    7.4    Global Cell Therapy Market (2017-2032) by End User
        7.4.1    Market Overview
        7.4.2    Hospitals and Clinics
        7.4.3    Regenerative Medicine Centers
        7.4.4    Diagnostic and Research Centers
        7.4.5    Others
    7.5    Global Cell Therapy Market (2017-2032) by Region
        7.5.1    Market Overview
        7.5.2    North America 
        7.5.3    Europe
        7.5.4    Asia Pacific
        7.5.5    Latin America
        7.5.6    Middle East and Africa
8    North America Cell Therapy Market (2017-2032)
    8.1    North America Cell Therapy Market (2017-2032) by Type
        8.1.1    Market Overview
        8.1.2    Stem Cell
            8.1.2.1    Bone Marrow Derived Mesenchymal Stem Cell
            8.1.2.2    Hematopoietic Stem Cells 
            8.1.2.3    Umbilical Cord Derived Stem Cell
            8.1.2.4    Adipose Derived Stem Cell
            8.1.2.5    Skin Stem Cells
            8.1.2.6    Induced Pluripotent Stem Cells
            8.1.2.7    Others
        8.1.3    Non-Stem Cell (Dendritic Cell, CART-Cell)
    8.2    North America Cell Therapy Market (2017-2032) by Type of Therapy 
        8.2.1    Market Overview
        8.2.2    Autologous
        8.2.3    Allogeneic
    8.3    North America Cell Therapy Market (2017-2032) by Therapeutic Area
        8.3.1    Market Overview
        8.3.2    Musculoskeletal Disorders
        8.3.3    Cardiovascular Diseases
        8.3.4    Neurological Disorders
        8.3.5    Oncological Disorders
        8.3.6    Dermatology
        8.3.7    Inflammatory And Autoimmune Disorders
        8.3.8    Others
    8.4    North America Cell Therapy Market (2017-2032) by End User
        8.4.1    Market Overview
        8.4.2    Hospitals and Clinics
        8.4.3    Regenerative Medicine Centers
        8.4.4    Diagnostic and Research Centers
        8.4.5    Others
    8.5    North America Cell Therapy Market (2017-2032) by Country
        8.5.1    United States of America
        8.5.2    Canada
9    Europe Cell  Therapy Market (2017-2032)
    9.1    Europe Cell Therapy Market (2017-2032) by Type
        9.1.1    Market Overview
        9.1.2    Stem Cell
            9.1.2.1    Bone Marrow Derived Mesenchymal Stem Cell
            9.1.2.2    Hematopoietic Stem Cells 
            9.1.2.3    Umbilical Cord Derived Stem Cell
            9.1.2.4    Adipose Derived Stem Cell
            9.1.2.5    Skin Stem Cells
            9.1.2.6    Induced Pluripotent Stem Cells
            9.1.2.7    Others
        9.1.3    Non-Stem Cell (Dendritic Cell, CART-Cell)
    9.2    Europe Cell Therapy Market (2017-2032) by Type of Therapy 
        9.2.1    Market Overview
        9.2.2    Autologous
        9.2.3    Allogeneic
    9.3    Europe Cell Therapy Market (2017-2032) by Therapeutic Area
        9.3.1    Market Overview
        9.3.2    Musculoskeletal Disorders
        9.3.3    Cardiovascular Diseases
        9.3.4    Neurological Disorders
        9.3.5    Oncological Disorders
        9.3.6    Dermatology
        9.3.7    Inflammatory And Autoimmune Disorders
        9.3.8    Others
    9.4    Europe Cell Therapy Market (2017-2032) by End User
        9.4.1    Market Overview
        9.4.2    Hospitals and Clinics
        9.4.3    Regenerative Medicine Centers
        9.4.4    Diagnostic and Research Centers
        9.4.5    Others
    9.5    Europe Cell Therapy Market (2017-2032) by Country
        9.5.1    United Kingdom
        9.5.2    Germany
        9.5.3    France
        9.5.4    Italy
        9.5.5    Others
10    Asia Pacific Cell Therapy Market (2017-2032)
    10.1    Asia Pacific Cell Therapy Market (2017-2032) by Type
        10.1.1    Market Overview
        10.1.2    Stem Cell
            10.1.2.1    Bone Marrow Derived Mesenchymal Stem Cell
            10.1.2.2    Hematopoietic Stem Cells 
            10.1.2.3    Umbilical Cord Derived Stem Cell
            10.1.2.4    Adipose Derived Stem Cell
            10.1.2.5    Skin Stem Cells
            10.1.2.6    Induced Pluripotent Stem Cells
            10.1.2.7    Others
        10.1.3    Non-Stem Cell (Dendritic Cell, CART-Cell)
    10.2    Asia Pacific Cell Therapy Market (2017-2032) by Type of Therapy 
        10.2.1    Market Overview
        10.2.2    Autologous
        10.2.3    Allogeneic
    10.3    Asia Pacific Cell Therapy Market (2017-2032) by Therapeutic Area
        10.3.1    Market Overview
        10.3.2    Musculoskeletal Disorders
        10.3.3    Cardiovascular Diseases
        10.3.4    Neurological Disorders
        10.3.5    Oncological Disorders
        10.3.6    Dermatology
        10.3.7    Inflammatory And Autoimmune Disorders
        10.3.8    Others
    10.4    Asia Pacific Cell Therapy Market (2017-2032) by End User
        10.4.1    Market Overview
        10.4.2    Hospitals and Clinics
        10.4.3    Regenerative Medicine Centers
        10.4.4    Diagnostic and Research Centers
        10.4.5    Others
    10.5    Asia Pacific Cell Therapy Market (2017-2032) by Country
        10.5.1    China
        10.5.2    Japan
        10.5.3    India
        10.5.4    ASEAN
        10.5.5    Australia
        10.5.6    Others
11    Latin America Cell Therapy Market (2017-2032)
    11.1    Latin America Cell Therapy Market (2017-2032) by Type
        11.1.1    Market Overview
        11.1.2    Stem Cell
            11.1.2.1    Bone Marrow Derived Mesenchymal Stem Cell
            11.1.2.2    Hematopoietic Stem Cells 
            11.1.2.3    Umbilical Cord Derived Stem Cell
            11.1.2.4    Adipose Derived Stem Cell
            11.1.2.5    Skin Stem Cells
            11.1.2.6    Induced Pluripotent Stem Cells
            11.1.2.7    Others
        11.1.3    Non-Stem Cell (Dendritic Cell, CART-Cell)
    11.2    Latin America Cell Therapy Market (2017-2032) by Type of Therapy 
        11.2.1    Market Overview
        11.2.2    Autologous
        11.2.3    Allogeneic
    11.3    Latin America Cell Therapy Market (2017-2032) by Therapeutic Area
        11.3.1    Market Overview
        11.3.2    Musculoskeletal Disorders
        11.3.3    Cardiovascular Diseases
        11.3.4    Neurological Disorders
        11.3.5    Oncological Disorders
        11.3.6    Dermatology
        11.3.7    Inflammatory And Autoimmune Disorders
        11.3.8    Others
    11.4    Latin America Cell Therapy Market (2017-2032) by End User
        11.4.1    Market Overview
        11.4.2    Hospitals and Clinics
        11.4.3    Regenerative Medicine Centers
        11.4.4    Diagnostic and Research Centers
        11.4.5    Others
    11.5     Latin America Cell Therapy Market (2017-2032) by Country
        11.5.1    Brazil
        11.5.2    Argentina
        11.5.3    Mexico
        11.5.4    Others
12    Middle East and Africa Cell Therapy Market (2017-2032)
    12.1    Middle East and Africa Cell Therapy Market (2017-2032) by Type
        12.1.1    Market Overview
        12.1.2    Stem Cell
            12.1.2.1    Bone Marrow Derived Mesenchymal Stem Cell
            12.1.2.2    Hematopoietic Stem Cells 
            12.1.2.3    Umbilical Cord Derived Stem Cell
            12.1.2.4    Adipose Derived Stem Cell
            12.1.2.5    Skin Stem Cells
            12.1.2.6    Induced Pluripotent Stem Cells
            12.1.2.7    Others
        12.1.3    Non-Stem Cell (Dendritic Cell, CART-Cell)
    12.2    Middle East and Africa Cell Therapy Market (2017-2032) by Type of Therapy 
        12.2.1    Market Overview
        12.2.2    Autologous
        12.2.3    Allogeneic
    12.3    Middle East and Africa Cell Therapy Market (2017-2032) by Therapeutic Area
        12.3.1    Market Overview
        12.3.2    Musculoskeletal Disorders
        12.3.3    Cardiovascular Diseases
        12.3.4    Neurological Disorders
        12.3.5    Oncological Disorders
        12.3.6    Dermatology
        12.3.7    Inflammatory And Autoimmune Disorders
        12.3.8    Others
    12.4    Middle East and Africa Cell Therapy Market (2017-2032) by End User
        12.4.1    Market Overview
        12.4.2    Hospitals and Clinics
        12.4.3    Regenerative Medicine Centers
        12.4.4    Diagnostic and Research Centers
        12.4.5    Others
    12.5     Middle East and Africa Cell Therapy Market (2017-2032) by Country
        12.5.1    Saudi Arabia
        12.5.2    United Arab Emirates
        12.5.3    Nigeria
        12.5.4    South Africa
        12.5.5    Others
13    Regulatory Framework
    13.1    Regulatory Overview
    13.2    US FDA
    13.3    EU EMA
    13.4    INDIA CDSCO
    13.5    JAPAN PMDA
    13.6    Others
14    Patent Analysis
    14.1     Analysis by Type of Patent
    14.2     Analysis by Publication Year
    14.3     Analysis by Issuing Authority
    14.4     Analysis by Patent Age
    14.5     Analysis by CPC Analysis
    14.6     Analysis by Patent Valuation 
    14.7     Analysis by Key Players
15    Clinical Trial Analysis
    15.1    Analysis by Trial Registration Year
    15.2    Analysis by Trial Status
    15.3    Analysis by Trial Phase
    15.4    Analysis by Therapeutic Area
    15.5    Analysis by Geography
16    Grant Analysis
    16.1    Analysis by Year
    16.2    Analysis by Amount Awarded
    16.3    Analysis by Issuing Authority
    16.4    Analysis by Grant Product
    16.5    Analysis by Funding Institute
    16.6    Analysis by Departments
    16.7    Analysis by Recipient Organization
17    Funding and Investment Analysis
    17.1     Analysis by Funding Instances
    17.2     Analysis by Type of Funding
    17.3     Analysis by Funding Amount
    17.4     Analysis by Leading Players
    17.5     Analysis by Leading Investors
    17.6     Analysis by Geography
18    Strategic Initiatives
    18.1     Analysis by Partnership Instances
    18.2     Analysis by Type of Partnership
    18.3     Analysis by Leading Players
    18.4     Analysis by Geography
19    Supplier Landscape
    19.1    Market Share Analysis, By Region (Top 5 Companies)
        19.1.1    Market Share Analysis: Global
        19.1.2    Market Share Analysis: North America
        19.1.3    Market Share Analysis: Europe
        19.1.4    Market Share Analysis: Asia-Pacific
        19.1.5    Market Share Analysis: Others
    19.2    Vericel Corporation 
        19.2.1    Financial Analysis
        19.2.2    Product Portfolio
        19.2.3    Demographic Reach and Achievements
        19.2.4    Mergers and Acquisitions
        19.2.5    Certifications 
    19.3    Kolon TissueGene Inc .
        19.3.1    Financial Analysis
        19.3.2    Product Portfolio
        19.3.3    Demographic Reach and Achievements
        19.3.4    Mergers and Acquisitions
        19.3.5    Certifications
    19.4    JCR Pharmaceuticals Co. Ltd 
        19.4.1    Financial Analysis
        19.4.2    Product Portfolio
        19.4.3    Demographic Reach and Achievements
        19.4.4    Mergers and Acquisitions
        19.4.5    Certifications
    19.5    MEDIPOST Co. Ltd .
        19.5.1    Financial Analysis
        19.5.2    Product Portfolio
        19.5.3    Demographic Reach and Achievements
        19.5.4    Mergers and Acquisitions
        19.5.5    Certifications
    19.6    Osiris (Mesoblast)
        19.6.1    Financial Analysis
        19.6.2    Product Portfolio
        19.6.3    Demographic Reach and Achievements
        19.6.4    Mergers and Acquisitions
        19.6.5    Certifications
    19.7    Stemedica Cell Technologies Inc .
        19.7.1    Financial Analysis
        19.7.2    Product Portfolio
        19.7.3    Demographic Reach and Achievements
        19.7.4    Mergers and Acquisitions
        19.7.5    Certifications
    19.8    ImmunoACT 
        19.8.1    Financial Analysis
        19.8.2    Product Portfolio
        19.8.3    Demographic Reach and Achievements
        19.8.4    Mergers and Acquisitions
        19.8.5    Certifications
    19.9    Castle Creek Biosciences, Inc .
        19.9.1    Financial Analysis
        19.9.2    Product Portfolio
        19.9.3    Demographic Reach and Achievements
        19.9.4    Mergers and Acquisitions
        19.9.5    Certifications 
    19.10    PHARMICELL Co. Ltd 
        19.10.1    Financial Analysis
        19.10.2    Product Portfolio
        19.10.3    Demographic Reach and Achievements
        19.10.4    Mergers and Acquisitions
        19.10.5    Certifications 
    19.11    ANTEROGEN.CO.LTD 
        19.11.1    Financial Analysis
        19.11.2    Product Portfolio
        19.11.3    Demographic Reach and Achievements
        19.11.4    Mergers and Acquisitions
        19.11.5    Certifications
    19.12    Novartis AG 
        19.12.1    Financial Analysis
        19.12.2    Product Portfolio
        19.12.3    Demographic Reach and Achievements
        19.12.4    Mergers and Acquisitions
        19.12.5    Certifications
    19.13    Celgene Corp. (Bristol-Myers Squibb Company)
        19.13.1    Financial Analysis
        19.13.2    Product Portfolio
        19.13.3    Demographic Reach and Achievements
        19.13.4    Mergers and Acquisitions
        19.13.5    Certifications
    19.14    Allogene Therapeutics Inc .
        19.14.1    Financial Analysis
        19.14.2    Product Portfolio
        19.14.3    Demographic Reach and Achievements
        19.14.4    Mergers and Acquisitions
        19.14.5    Certifications
    19.15    Stempeutics Research Pvt. Ltd 
        19.15.1    Financial Analysis
        19.15.2    Product Portfolio
        19.15.3    Demographic Reach and Achievements
        19.15.4    Mergers and Acquisitions
        19.15.5    Certifications
20    Global  Cell Therapy Market – Distribution Model (Additional Insight)
    20.1     Overview 
    20.2     Potential Distributors 
    20.3     Key Parameters for Distribution Partner Assessment 
21    Key Opinion Leaders (KOL) Insights (Additional Insight)
22    Payment Methods (Additional Insight)

    22.1    Government Funded
    22.2    Private Insurance
    22.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

 

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

 

**The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.

Purchase Full Report

Datasheet

$ 2969     $2699
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5499     $4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 6599     $5999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 7699     $6999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER